Literature DB >> 20172062

Central serous chorioretinopathy: a personal perspective.

Lawrence A Yannuzzi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20172062     DOI： 10.1016/j.ajo.2009.11.017

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN： 0002-9394            Impact factor:   5.258


× No keyword cloud information.
  61 in total

1.  Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy.

Authors:  Jasmine H Francis; Larissa A Habib; David H Abramson; Lawrence A Yannuzzi; Murk Heinemann; Mrinal M Gounder; Rachel N Grisham; Michael A Postow; Alexander N Shoushtari; Ping Chi; Neil H Segal; Rona Yaeger; Alan L Ho; Paul B Chapman; Federica Catalanotti
Journal:  Ophthalmology       Date:  2017-07-12       Impact factor: 12.079

2.  Intravitreal aflibercept for choroidal neovascularisation complicating chronic central serous chorioretinopathy.

Authors:  Geoffrey K Broadhead; Andrew Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-12-31       Impact factor: 3.117

3.  Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome.

Authors:  N K Yadav; C Jayadev; A Mohan; P Vijayan; R Battu; S Dabir; B Shetty; R Shetty
Journal:  Eye (Lond)       Date:  2015-01-23       Impact factor: 3.775

4.  Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy.

Authors:  Andrea Russo; Raffaele Turano; Francesco Morescalchi; Elena Gambicorti; Anna Cancarini; Sarah Duse; Ciro Costagliola; Francesco Semeraro
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-03-10       Impact factor: 3.117

Review 5.  25th RCOphth Congress, President's Session paper: 25 years of progress in medical retina.

Authors:  J M Gibson
Journal:  Eye (Lond)       Date:  2014-07-04       Impact factor: 3.775

Review 6.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

7.  Association between CFH single nucleotide polymorphisms and response to photodynamic therapy in patients with central serous chorioretinopathy.

Authors:  Dandan Linghu; Hui Xu; Zhiqiao Liang; Tingting Gao; Zhaojun Lin; Xiaoxin Li; Lvzhen Huang; Mingwei Zhao
Journal:  Int Ophthalmol       Date:  2020-01-10       Impact factor: 2.031

8.  Axial length in unilateral idiopathic central serous chorioretinopathy.

Authors:  Hoseok Moon; Dae Yeong Lee; Dong Heun Nam
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

9.  Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Helena Vasconcelos; Inês Marques; A Rita Santos; Pedro Melo; Isabel Pires; João Figueira; José Faria de Abreu; M Luz Cachulo; Rufino Silva
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-02-07       Impact factor: 3.117

10.  Role of the Complement System in Chronic Central Serous Chorioretinopathy: A Genome-Wide Association Study.

Authors:  Rosa L Schellevis; Elon H C van Dijk; Myrte B Breukink; Lebriz Altay; Bjorn Bakker; Bobby P C Koeleman; Lambertus A Kiemeney; Dorine W Swinkels; Jan E E Keunen; Sascha Fauser; Carel B Hoyng; Anneke I den Hollander; Camiel J F Boon; Eiko K de Jong
Journal:  JAMA Ophthalmol       Date:  2018-10-01       Impact factor: 7.389
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.